<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57115">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02031133</url>
  </required_header>
  <id_info>
    <org_study_id>SPC3649-207E</org_study_id>
    <nct_id>NCT02031133</nct_id>
  </id_info>
  <brief_title>Long-term Extension to Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C</brief_title>
  <official_title>Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin in Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santaris Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santaris Pharma A/S</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study SPC3649-207E is designed as an extension study to the prior protocol to provide
      additional long-term safety and efficacy information for subjects participating in Study
      SPC3649-207.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Safety and tolerability will be assessed by evaluation of liver ultrasound, physical examinations, vital signs, and routine laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis).</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HCV RNA level from baseline through end of study.</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Viral resistance analysis through end of study.</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The miR-122 seed sites in HCV RNA from subjects following viral breakthrough or relapse will be subjected to genotypic sequence analysis.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Miravirsen</arm_group_label>
    <description>Subjects who were enrolled in and received miravirsen doses in study SPC3649-207 will be observed for safety and efficacy in the 3-year long-term extension study SPC3649-207E. No study medication will be given during this extension study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miravirsen</intervention_name>
    <arm_group_label>Miravirsen</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Null responder subjects with CHC genotype 1 virus infection who have participated in study
        SPC3649-207.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Participated in study SPC3649-207

        Exclusion Criteria:

        - Received investigational drug therapy after discontinuation, termination, or successful
        completion of study SPC3649-207
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maribel Rodriguez-Torres, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion de Investigacion de Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundacion de Investigation de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antisense</keyword>
  <keyword>miR-122 antagonist</keyword>
  <keyword>host factor</keyword>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Hepatitis C</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon Alfa-2a</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
